Advanced Solutions
for Advanced Pathology
Galectin-3 (9C4)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45142 IMPATH Galectin-3 RTU M (9C4)
50 Tests
44291 Galectin-3 RTU M (9C4)
7 ml Ready To Use
44604 Galectin-3 0,1 M (9C4)
100 µl liquid Concentrated
44605 Galectin-3 1 M (9C4)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Papillary thyroid carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Galectin-3 is a 30 kD protein, a member of the b-galactosidase-binding lectin family. It has been implicated in processes including cell growth,
adhesion, inflammation, mRNA processing, and apoptosis. It is predominantly expressed in the nucleus of epithelial and immune cells. Galectin-3
is found in neutrophils and vascular endothelium. Over-expression is related to malignant transformation and metastasis in carcinomas of
the breast, colon, tongue, liver, and thyroid but is absent in thyroid adenomas. Anti-galectin-3 is utilized for differentiation between follicular
adenoma, follicular carcinoma, and papillary carcinoma of the thyroid, and is best used in a panel with other markers such as anti-CK19 and
anti-HBME-1. Anti-galectin-3 shows the most intense staining in the advancing tongues of minimally invasive follicular carcinoma and may be
helpful in differentiating a follicular adenoma from a minimally invasive carcinoma.
Thyroid: Malignant vs. Benign
Galectin-3
Thyroglobulin
Calcitonin
CK 19
TTF-1
HBME-1
Papillary Carcinoma
+
+
-
+
+
+
Follicular Carcinoma
+
+
-
-/+
+
+/-
Medullary Carcinoma
-
-
+
+/-
+
+
Benign Thyroid
-
+
-
-
+
-
Reference
1. Inohara H, et al. Cancer. 1999; 85:2475-84.
2. Herrmann ME, et al. Arch Pathol Lab Med. 2002; 126:710-713.
3. Papotti M, et al. European Journal of Endocrinology. 2002; 147:515-521.
121
